ABCL (AbCellera Biologics) Other Long-Term Liabilities: $11.32 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABCL AbCellera Biologics Inc ABCL
60 GF Score
Price $5.86
GF Value $5.23
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is AbCellera Biologics Other Long-Term Liabilities?

AbCellera Biologics ABCL -1.93% 60 Other Long-Term Liabilities is $11.32 Mil as of Mar. 2026. GuruFocus rates ABCL with a GF Score™ of 60/100 and a GF Value™ of $5.23 (Modestly Overvalued). The stock has 3 warning signs investors should review.

AbCellera Biologics's other long-term liabilities for the quarter that ended in Mar. 2026 was $11.32 Mil.

AbCellera Biologics's quarterly other long-term liabilities increased from Sep. 2025 ($1.39 Mil) to Dec. 2025 ($4.77 Mil) and increased from Dec. 2025 ($4.77 Mil) to Mar. 2026 ($11.32 Mil).

AbCellera Biologics's annual other long-term liabilities increased from Dec. 2023 ($5.91 Mil) to Dec. 2024 ($7.17 Mil) but then declined from Dec. 2024 ($7.17 Mil) to Dec. 2025 ($4.77 Mil).

AbCellera Biologics Other Long-Term Liabilities Related Terms

AbCellera Biologics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for AbCellera Biologics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics Other Long-Term Liabilities Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial 1.73 3.09 5.91 7.17 4.77

AbCellera Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.62 1.56 1.39 4.77 11.32
ABCL
60GF Score
AbCellera Biologics Inc ABCL
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbCellera Biologics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $11.32 Mil mean?
AbCellera Biologics (ABCL) has a Other Long-Term Liabilities of $11.32 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AbCellera Biologics and its competitors.
Is AbCellera Biologics' Other Long-Term Liabilities too high?
AbCellera Biologics' current Other Long-Term Liabilities is $11.32 Mil. Overall, AbCellera Biologics has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Other Long-Term Liabilities compare to AGIO and KOD?
AbCellera Biologics' Other Long-Term Liabilities of $11.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current Other Long-Term Liabilities is $11.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.23, compared to a current price of $5.86 — trading 12% above its estimated fair value. The current Other Long-Term Liabilities is $11.32 Mil. AbCellera Biologics' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Other Long-Term Liabilities is $11.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $5.86 is trading 12% above its estimated GF Value™ of $5.23. GuruFocus considers AbCellera Biologics to be Modestly Overvalued.

Key valuation signals for ABCL:

  • Other Long-Term Liabilities: $11.32 Mil
  • GF Value™: $5.23 vs. price of $5.86 (12% above fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
60GF Score

Get the complete analysis for ABCL

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.86
Price
$5.23
GF Value